4:07 PM
 | 
Apr 05, 2013
 |  BC Extra  |  Company News

Ambrx, Astellas in ADC cancer deal

Ambrx Inc. (La Jolla, Calif.) partnered with Astellas Pharma Inc. (Tokyo:4503) to discover and develop antibody-drug conjugates (ADCs) for undisclosed cancer indications. Ambrx will...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >